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PVIEWPOINT
In Search of the “Vulnerable Plaque”
Can it Be Localized and Will Focal Regional
Therapy Ever Be an Option for Cardiac Prevention?
John A. Ambrose, MD, FACC
Fresno, California
The search to find the location of future plaque ruptures or plaque erosions leading to myocardial infarction (so-
called “vulnerable plaques”) is an important area of cardiovascular research. Systemic therapy, including use of
statins, targets the vulnerable patient. However, adverse events cannot be completely eliminated with the appro-
priate application of systemic therapies and thus has given rise to the possibility of local or regional therapy of
“vulnerable plaques” to prevent future events. Until now, no criteria have been developed for consideration of
this therapy. For such a strategy to work, there should be several prerequisites. These involve the identification
of susceptible lesions, the number of lesions, their natural history, and proof that an interventional technique is
preferable to medical therapy alone. The greatest deficiency relates to the fact that until the natural history of
presumed “vulnerable plaques” is known one can never truly identify what constitutes a “vulnerable plaque.”
Much work needs to be done in this area, but ongoing and new trials should provide important information that
could potentially change drastically how coronary artery disease is diagnosed and treated. (J Am Coll Cardiol
2008;51:1539–42) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.041a
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Tt is no secret to anyone in the health care field that
revention of adverse cardiac events such as myocardial
nfarction (MI) and sudden cardiac death is of paramount
mportance. Although all patients with documented coro-
ary artery disease or a coronary artery disease equivalent are
ow considered candidates for systemic therapies such as
spirin, cholesterol-lowering with statins, and angiotensin-
onverting enzyme inhibitors, adverse events still occur in
pite of aggressive management. Several recent large ran-
omized clinical trials have shown that in patients treated
ith high-dose statins, even optimal low-density lipopro-
ein cholesterol levels do not eliminate all events on
ollow-up (1–3).
Thus, in addition to systemic therapy, investigators have
een looking at the potential role for local or regional
herapy for the “vulnerable plaque” (4). If one can identify a
vulnerable plaque” and therapeutically reduce its vulnera-
ility before symptoms arise, this might prevent subsequent
nfarctions. On the basis of the aforementioned trial data of
esidual cardiovascular events in patients receiving maxi-
um therapy and the known histopathology of lesions
esponsible for MI or sudden coronary death, the concept of
dentifying and treating “vulnerable plaque” with local or
egional therapy has become a potential goal for future
anagement. This journal continues to publish several
rom University of California, San Francisco, Fresno, California.n
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007, accepted December 17, 2007.rticles concerning “vulnerable plaque” pathophysiology,
iagnosis, and potential management (5–8), and each year
everal national and international symposia highlight new
nformation on “vulnerable plaque” and the prospects for
ocal or regional therapy. However, until now there have
een no objective criteria developed for the use of such local
r regional therapy.
rerequisites for a Local
r Regional Approach to “Vulnerable Plaque”
n my opinion, there are at least 5 prerequisites to adopt
uch an approach for otherwise asymptomatic “vulnerable
laques” (Table 1).
Vulnerable plaque” caused by a thin-capped fibroathe-
oma can be identified with modern technology. The
hin-capped fibroatheroma (TCFA) is presumed, on the
asis of several lines of investigations including pathologic
tudies from patients dying with MI or sudden coronary
eath, to be the most common substrate for coronary
hrombosis causing acute MI (9). Several techniques in
arious stages of development and investigation, including
ntravascular ultrasound (IVUS) and its offspring palpogra-
hy and virtual histology, optical coherence tomography
OCT), and near infrared spectroscopy, among others, can
dentify these lesions (10–13). Furthermore, the predomi-
ance of lesions responsible for ST-segment elevation MI
ccurs in the proximal segments of the coronary artery (14).
hus, in an otherwise asymptomatic individual or in a
onculprit artery in patients presenting for intervention of
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Vulnerable Plaque and Local Therapy April 22, 2008:1539–42another vessel, these lesions
could be reached and potentially
identified.
A “vulnerable plaque” caused
by plaque erosion should be
identifiable. For a local tech-
nique to be completely effective,
all lesions responsible for MI
should be identifiable. At least
one-third of lesions responsible
or major coronary thrombi on pathologic analysis are
econdary to plaque erosions (15). Because the underlying
laque is not necessarily lipid-rich, inflamed, or possessing a
hin cap, the techniques already described might not identify
uch lesions. Increased coagulability of the blood, the presumed
echanism most likely responsible for or associated with
laque erosions, might not target specific lesions that are easily
dentifiable by the aforementioned techniques. Thus, MIs
aused by plaque erosions (or any lesion other than a TCFA)
ave not been a specific target for those who are attempting to
dentify “vulnerable plaques” before an event.
The least frequent histologic plaque associated with
hrombosis is a calcified nodule and is seen in up to 10% of
ulprit thrombosed plaques on autopsy (16). Although other
ypes of “vulnerable plaques” have been proposed (17), the 3
forementioned (TCFA, erosions, and nodules) are consid-
red by consensus to account for nearly all major coronary
hrombi at autopsy (16). No vulnerable plaque detector is
resently addressing the calcified nodule.
he number of “vulnerable plaques” is known, and the
umber is limited. For a local/regional approach to be
easible, the number must be limited and, if not limited by
umber, “vulnerable plaques” should be limited to specific
reas of the coronary artery that can be effectively treated.
everal in vivo studies have tried to evaluate the number of
resumed “vulnerable plaques” with IVUS, angioscopy, or
CT (18–20). Pathologic studies have also been used to
dentify the number of TCFA in patients dying from
oronary or noncoronary events. Several in vivo studies have
dentified various types of lesions, including ruptured
symptomatic plaques with IVUS, yellow (lipid-rich)
laques with angioscopy, and intact, thin-capped lesions
ith OCT. Most studies suggest there are no more than 2
Abbreviations
and Acronyms
IVUS  intravascular
ultrasound
OCT  optical coherence
tomography
TCFA  thin-capped
fibroatheroma
rerequisites for a LocalR gional App oach to “Vulnerable Plaque”
Table 1 Prerequisites for a Localor Regional Approach to “Vulnerable Plaque”
1 “Vulnerable plaque” caused by a thin-capped fibroatheroma can be identified
with modern technology.
2 A “vulnerable plaque” caused by plaque erosion should be identifiable.
3 The number of “vulnerable plaques” is known, and the number is limited.
4 The natural history of a “vulnerable plaque” has been identified in patients
treated with optimal systemic therapies.
5 An interventional approach applied locally or regionally to an asymptomatic
“vulnerable plaque” is proven to reduce future events relative to the bestr
systemic medical therapy.o 3 such lesions/patient even in those presenting with MI
n another vessel or at another site (21).
There is, however, a fundamental flaw in this research.
ithout natural history studies, no one really knows what a
vulnerable plaque” looks like. Pathologic studies have
hown us the characteristics of the culprit plaques respon-
ible for MI or sudden coronary death. These are already
uptured plaques containing intracoronary thrombus. The
vulnerable plaque” before an event could be a TCFA with
n intact cap. Yet, how much plaque lipid, necrotic core, or
nflammation is needed? And how thin must the cap be to
all it vulnerable on an initial evaluation? Another potential
andidate for a “vulnerable plaque” might be an already
uptured but asymptomatic plaque such as those detected by
VUS at nonculprit sites from patients undergoing inter-
ention with an acute syndrome. Until the proper long-term
tudies have been performed, this is in my opinion the most
ritical deficiency for those attempting to identify and
herapeutically alter “vulnerable plaque” (Fig. 1).
he natural history of a “vulnerable plaque” has been
dentified in patients treated with optimal systemic
herapies. As mentioned earlier, only with natural history
tudies will one ever hope to understand what constitutes
vulnerable plaque.” Furthermore, these studies must assess
hrough long-term follow-up the propensity for such plaques
o develop a hard cardiovascular end point (vide infra) in
atients receiving optimum systemic therapies, including aspi-
in, statins to an optimum low-density lipoprotein chlolesterol
evel, and the use of appropriate doses of angiotensin-
onverting enzyme inhibitors and beta blockers (22). Such
atural history studies as described in the preceding text must
e large, prospective, and follow-up all potential “vulnerable
laques,” particularly those that remain asymptomatic on
ollow-up. Initial and follow-up studies must use various
maging techniques to identify presumed “vulnerable plaques.”
ngoing natural history studies such as PROSPECT (Provid-
ng Regional Observations to Study Predictors of Events in the
oronary Tree) will soon report their initial results. However,
symptomatic patients will not undergo repeat imaging and
herefore this study can not answer all important issues related
o natural history of presumed vulnerable lesions.
Ideally, natural history studies should last for several years
nd target high-risk patients, such as in the PROSPECT
rial. Trials would be greatly facilitated by a noninvasive
echnique to serially follow and identify “vulnerable plaque.”
nfortunately, such a technique is not presently available.
hatever technique is shown to identify a true “vulnerable
laque” on natural history, it must also have a very high
ensitivity and specificity.
n interventional approach applied locally or regionally
o an asymptomatic “vulnerable plaque” is proven to
educe future events relative to the best systemic medical
herapy. For a local/regional approach to an otherwise
symptomatic plaque to be effective, what should the therapy
onsist of? Of course, it must be safer and more effective in
educing events than the best medical therapies available.
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April 22, 2008:1539–42 Vulnerable Plaque and Local Therapyresently, there is no ideal interventional technique for such
symptomatic plaques. Perhaps, newer generations of drug-
luting stents (bioabsorbable stents?) could be the answer, but
uperiority over optimal medical therapy alone will have to be
roven in a very large randomized trial (23). A trial such as this
ust have as its primary end point only hard cardiovascular
vents, including fatal and nonfatal acute MI and definite
nstable angina, because these are most likely to be caused by
isruption/thrombosis of vulnerable lesions (22).
Furthermore, these studies will be complicated by the
ikelihood of a cardiac event for a proven “vulnerable
laque.” For example, if natural history studies indicate that
nly 5% of a given plaque type as identified will develop an
vent on follow-up (number needed to treat [NNT]  20),
ll 20 of these plaques will need to be treated with a new and
xpensive procedure to prevent 1 event. What are the
onsequences? If, however, the NNT to prevent a cardiac
Figure 1 What Is a Vulnerable Plaque?
In the upper panel, the middle figure shows a presumed vulnerable plaque, a
thin-capped atheroma with a large lipid/necrotic core and a thin fibrous cap
infiltrated by inflammatory cells, which is thought to be the immediate precur-
sor of symptomatic thrombosed plaque (upper right figure). However, as shown
in the lower panel, a “vulnerable plaque” might not be such an easy diagnosis to
make with 1 or more invasive/noninvasive techniques. The true precursor to a
symptomatic thrombosed plaque might depend on such factors as the exact cap
thickness, size of the lipid/necrotic core, inflammatory cell volume, thrombogenic-
ity of the blood, and so forth. Figure illustration by Rob Flewell.vent is low at, for example, 5, then a procedure on all ofhese plaques could make sense. These and other questions
ill need to be addressed in future trials.
onclusions
he search for the “vulnerable plaque” and evidence-based
roof that a local or regional approach will successfully
educe events will be extremely difficult and time-
onsuming, requiring several years of natural history and
herapeutic trials. On the basis of the 5 prerequisites, at
resent, only the first is possible and the other 4 require further
tudy. Even if the site of a future plaque erosion cannot be
dentified, fulfilling the other criteria could provide data to
upport a focal approach to other “vulnerable plaques,” such as
he TCFA. Although the process to prove efficacy will be
aunting, appropriately sized and well-designed trials should
dd vital information about the pathophysiology of coronary
rtery disease and could change profoundly how coronary
rtery disease is diagnosed and treated.
eprint requests and correspondence: Dr. John A. Ambrose,
823 Fresno Street, Fresno, California 93721. E-mail: jamambrose@
ahoo.com.
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